Health and life sciences organisations in Australia are navigating the most significant regulatory transformation in a generation, with the new Aged Care Act’s rights-based framework, the National Disability Insurance Scheme Amendment (Securing the NDIS for Future Generations) Bill, and mounting workforce and funding pressure converging at once. Boards are being forced to appoint chief executives and chief operating officers who can rebuild trust with regulators, funders and the public simultaneously, while running increasingly complex, capital intensive operations. Getting this appointment wrong in the current environment does not just cost performance, it exposes the organisation to regulatory, reputation and, in aged and child care, and disability services, genuine safety risk.

Lisa Maloney leads Omera Partners’ Health, Life Sciences practice, and the practice has built nearly two decades of relationships across Australia’s health, aged care and community services sector. Before taking a brief in health and life sciences, the first step is understanding the organisation’s funding model, whether Commonwealth funded, private, mission driven not for profit or ASX listed, its regulatory exposure, and whether the leadership gap is about growth, turnaround or succession.

The practice’s network runs deepest across aged and child care providers, including faith based and mission driven operators, pathology and diagnostics businesses, and government owned health and human services entities, with growing coverage across private and listed health and life sciences more broadly. Boards are consistently engaged on confidential succession questions long before a role is publicly vacant, not only organisations already running an open search.

Market perspective

The next 24 months will be shaped by the practical implementation of the new Aged Care Act’s Statement of Rights, the staged roll out of Support at Home, and the National Disability Insurance Scheme reforms designed to shift everyday support back into mainstream and community services. Boards need executives who treat compliance not as a cost centre but as the new baseline for community and government trust, while using data and artificial intelligence enabled rostering, care planning and fraud detection to manage rising cost pressure without compromising care quality. Health and life sciences leadership is shifting from operators who manage services to executives who can navigate government relationships, funding reform and consumer expectations at the same time, whilst also being focused on profitable growth and industry shaping.

‍Questions boards and chief executives should ask before appointing a health and life sciences leader

1.   Has this leader operated inside a rights-based or heavily regulated funding model before, and do they understand the practical difference between compliance and genuine trust with regulators and the public?

2.   Does this leader have a credible plan for using data and artificial intelligence to manage workforce and funding pressure without compromising the quality or safety of care?

3.   Is the organisation appointing for the compliance environment of today, or for a sector that will look materially different once the Aged Care Act reforms, Child Care and NDIS changes are fully implemented?

4.   Does this leader understand the realities of delivering care in regional and remote Australia, not just metropolitan operating models?

5.   Are we appointing someone who can rebuild trust with government, funders and the community simultaneously, or only manage one of those relationships well?

Working with Omera Partners

Omera Partners advises boards and chief executives on senior leadership appointments across health, aged care, child care, disability services and life sciences, from mission driven not for profit providers to ASX listed and government owned health and human services entities. When a single appointment can determine whether an organisation rebuilds trust with regulators, funders and the community or falls further behind a sector being reshaped in real time, the search deserves a firm with genuine depth across this sector’s full funding and regulatory spectrum. That is the standard Omera Partners brings to every health and life sciences appointment.